Sign in

David W. Benfer

Lead Independent Director at Stereotaxis
Board

About David W. Benfer

David W. Benfer, 78, is a long-tenured independent director of Stereotaxis, Inc., serving on the board since February 2005 and as Lead Independent Director since February 2015 . He is Chairman of The Benfer Group LLC (since 2010), and previously held CEO roles at Hospital of Saint Raphael (1999–2009), Provena-Saint Joseph/Morris Health Network (1992–1999), and Henry Ford Hospital (1985–1992) . He earned an MBA from Xavier University and a BSBA from Wittenburg University, and is a Fellow of the American College of Healthcare Executives (ACHE) .

Past Roles

OrganizationRoleTenureCommittees/Impact
Hospital of Saint Raphael / Saint Raphael Healthcare SystemPresident & CEO1999–2009Led system; governance and risk insights for tech adoption
Provena-Saint Joseph/Morris Health Network (Joliet, IL)President & CEO1992–1999Hospital network leadership
Henry Ford Health System / Henry Ford Hospital (Detroit)SVP Hospital & Urban Affairs; CEO Henry Ford Hospital1985–1992Health system operations
American College of Healthcare Executives (ACHE)Chairman; Board of GovernorsChair 1998–1999; Governor 1992–2000Industry leadership; ACHE Fellow since 1981
Catholic Health AssociationBoard Member2003–2008Sector governance

External Roles

OrganizationRoleTenureNotes
The Benfer Group LLCChairman2010–PresentAdvisory services to healthcare providers/suppliers
The John and Mable Ringling Museum of Art Foundation, Inc.Board MemberCurrentFlorida state museum foundation (non-profit)

Board Governance

  • Independence: The Board determined Mr. Benfer was independent under NYSE American standards; only David L. Fischel and Dr. Nathan Fischel were non-independent in 2024 .
  • Lead Independent Director: Serves as Lead Independent Director since Feb 2015; leads regular executive sessions of independent directors and provides feedback to management .
  • Committee assignments (2024 year-end):
    • Audit Committee: Member (Committee all members independent and financially sophisticated) .
    • Compensation Committee: Member (Committee members independent) .
    • Nominating & Corporate Governance Committee: Chair .
  • Attendance: Board held 6 meetings; all incumbent directors attended 100% of Board and committee meetings; Benfer attended the 2024 Annual Meeting .

Fixed Compensation

Component2024 AmountNotes
Annual retainer (cash)$0 No cash fees were paid to directors in 2024
Committee chair/member feesNot disclosed No separate cash fees disclosed; only RSUs program detailed
Meeting feesNot disclosed Not specified in proxy
Expense reimbursements≤ $10,000 Reimbursements did not exceed $10,000 and are excluded from comp table

Performance Compensation

Component2024 AmountGrant StructureVesting Terms
Stock awards (RSUs)$200,000 Annual RSUs paid in two $100,000 semi-annual installments (Jan 1, Jul 1), paid in arrears, number of units based on adjusted closing price Director elects vesting: either immediate on grant or deferred to earliest of 5th anniversary, end of Board service, or change of control
Option awards$0 None granted to directors in 2024 N/A

Performance metrics tied to director compensation:

MetricUsed?Disclosure
Financial/operational targets (revenue/EBITDA/TSR/ESG)NoNo performance metrics were disclosed for non-employee director RSU awards; program is time-based with elective vesting schedule

Other Directorships & Interlocks

CategoryDetails
Current public company boardsNone disclosed for Mr. Benfer in the proxy
Private/non-profit boardsRingling Museum of Art Foundation (non-profit)
Interlocks with competitors/suppliers/customersNone disclosed
Familial/related ties impacting independenceNone disclosed regarding Mr. Benfer; note Dr. Nathan Fischel is father of CEO David L. Fischel (context for board independence assessment)

Expertise & Qualifications

  • Healthcare leadership: Decades of CEO and senior leadership in hospital systems; governance and risk expertise relevant to technology adoption in medical settings .
  • Industry credentials: ACHE Fellow; former ACHE Chairman and Governor .
  • Education: MBA (Xavier University), BSBA (Wittenburg University) .
  • Financial oversight: Audit Committee member; Board determined Audit Committee members are financially sophisticated .

Equity Ownership

ItemAmountAs-of DateNotes
Beneficial ownership (common)463,304 shares Mar 17, 2025Includes 2,700 shares held by spouse and 210,255 shares held by Benfer Family Trust TTEE
Ownership % of common<1% Mar 17, 2025Company had 85,979,662 common shares outstanding
RSUs outstanding244,945 units (unvested) Dec 31, 2024None vested as of 12/31/24
Options (exercisable/unexercisable)None disclosed Mar 17, 2025No director option awards in 2024
Pledged sharesNone disclosedN/ANo pledging disclosures for Mr. Benfer in proxy

Insider Trading & Section 16 Compliance

ItemStatusNotes
Section 16(a) filingsTimelyBased on company review and written representations, all insiders timely filed in the last fiscal year
Insider trading policyIn placeApplies to directors and prohibits trading when aware of MNPI; policy filed as 2024 10-K exhibit

Governance Assessment

  • Strengths: Long-tenured independent director with healthcare system CEO experience; Lead Independent Director role with active leadership of executive sessions; committee breadth (Audit member; Compensation member; Nominating & Governance Chair); 100% attendance in 2024; independence affirmed; equity-only director compensation increases alignment with shareholders .
  • Pay/Ownership Alignment: $200,000 annual RSU grants and significant unvested RSU holdings (244,945 units) signal longer-term orientation; no cash fees; elective vesting structure includes deferred vesting until service end or change-of-control .
  • Conflicts/Related-Party: No related-party transactions disclosed involving Mr. Benfer; Board employs review/approval process and Code of Conduct to manage conflicts .
  • RED FLAGS: None disclosed specific to Mr. Benfer (no pledging/hedging disclosures; independence affirmed; full attendance) .